FDA Approves Fruquintinib in Refractory Metastatic Colorectal Cancer
FDA Actions & Updates: Posts,
The FDA has approved fruquintinib, an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been…
The FDA has approved fruquintinib, an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who have been…
THURSDAY, July 20, 2023 (HealthDay News) — For patients with refractory metastatic colorectal cancer, fruquintinib treatment…
Bookmark 1. Overall survival was significantly greater in the fruquintinib group versus placebo. 2. The majority of adverse…
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre…
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy…